Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Summary not available.
Insmed Incorporated (Nasdaq: INSM) reported Q3 2021 revenue of $46.8 million, up from $43.6 million in Q3 2020. The company experienced a GAAP net loss of $112.7 million or $0.96 per share, widening from a loss of $63.7 million or $0.63 per share year-over-year. Key developments include strong initial uptake of ARIKAYCE in Japan and ongoing clinical trials for brensocatib and TPIP. Insmed ended the quarter with $846.6 million in cash and cash equivalents, positioning it well for future investments and growth.
Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.
Insmed announced on October 5, 2021, that it has granted inducement awards to 11 new employees. These awards consist of options to purchase a total of 67,760 shares of common stock at an exercise price of $27.38, the closing price on the grant date. The options feature a ten-year term with a four-year vesting schedule, where 25% vests after the first year and 12.5% every six months thereafter, contingent on continued employment. This initiative is aligned with NASDAQ Listing Rule 5635(c)(4).
On September 3, 2021, Insmed announced the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 394,730 shares at an exercise price of $29.13 per share, matching the closing price on September 1, 2021. The options come with a ten-year term and a four-year vesting schedule, with 25% vesting after the first year. Insmed focuses on treating serious and rare diseases with a robust therapy pipeline alongside its first-in-disease product approved in multiple regions.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on serious and rare diseases, will participate in several upcoming virtual investor events. These include the Citi BioPharma Virtual Conference on September 8, Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 13, among others. Each session will be webcast and available for 30 days following. Insmed aims to transform patient lives with its therapies, including a first-in-disease treatment for a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees as part of its hiring strategy. The awards, compliant with NASDAQ Listing Rule 5635(c)(4), included options to purchase 42,320 shares of common stock at an exercise price of $24.13, the closing price on August 2, 2021. The options come with a ten-year term, featuring a four-year vesting schedule. Insmed aims to address serious and rare diseases with its therapies, focusing on unmet medical needs.
Insmed Incorporated (Nasdaq:INSM) reported Q2 2021 financial results, showcasing total revenue of $45.4 million, up from $42.5 million in Q2 2020. The company's net loss widened to $117.3 million or $1.07 per share, compared to a loss of $61.9 million or $0.64 per share year-over-year. Key developments include the launch of ARIKAYCE in Japan, ongoing clinical trials for brensocatib, and advancements in TPIP. Insmed has cash reserves of $928.3 million and plans further investments in product commercialization and clinical activities.
Insmed Incorporated (Nasdaq: INSM) will announce its Q2 2021 financial results on August 5, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Investors can join the call by dialing (844) 200-6205 (domestic) or +44-208-0682-558 (international), with an access code of 711350. The call will also be webcast live on their website. A replay will be available after the call and accessible until September 6, 2021. Insmed is focused on treating serious and rare diseases.
Insmed Incorporated (Nasdaq: INSM) announced on July 8, 2021, the granting of inducement awards to 12 new employees, approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase 72,350 shares of common stock at an exercise price of $29.47, the closing price on July 1, 2021. The options have a ten-year term with a four-year vesting schedule. Insmed is focused on developing therapies for serious and rare diseases, including a commercial product approved in the U.S., Europe, and Japan.